Duxazosin in men with lower urinary tract symptoms: Urodynamic evaluation at 15 months

Urology

Volumn 50, Issue 2, 1997, Pages 229-233

  Gerber, Glenn S ^a,b   Contreras, Barbara A ^a   Zagaja, Gregory P ^a   Kim, Jae H ^a   Steinberg, Gary D ^a   Rukstalis, Daniel B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; BLADDER NECK STENOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SYMPTOMATOLOGY; URINARY TRACT DISEASE; URODYNAMICS; BLADDER OBSTRUCTION; COMPARATIVE STUDY; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOXAZOSIN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; TIME FACTORS; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 0030610820     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00189-1     Document Type: Article

References (17)

1. Gleason DM, and Bottaccini MR: Effect of terazosin on urine storage and voiding in the aging male with prostatism. Neurourol Urodyn 13: 1-12, 1994.
2. Gerber GS, Kim JH, Contreras BA, Steinberg GD, and Rukstalis DB: An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 47: 840-844, 1996.
3. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJG, and Abrams P: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50-56, 1994.
4. Chapple CR, Stott M, Abrams PH, Christmas TJ, and Milroy EJG: A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia. Br J Urol 70: 285-294, 1992.
5. Hedlund H, Andersson KE, and Ek A: Effects of prazosin in patients with benign prostatic obstruction. J Urol 130: 275-278, 1983.
6. Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, and Painter MR: Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 154: 205-206, 1995.
7. Abrams P: Objective evaluation of bladder outlet obstruction. Br J Urol 76 (suppl 1): 11-15, 1995.
8. Lim CS, and Abrams P: The Abrams-Griffiths nomogram. World J Urol 13: 34-39, 1995.
9. Lim CS, Reynard J, Cannon A, and Abrams PH: The Abrams-Griffiths number: a simple way to quantify bladder outlet obstruction. Neurourol Urodyn 13: 475-476, 1994.
10. Lepor H, Williford WO, Barry MJ, et al, for the Veteran Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: 533-539, 1996.
11. Lepor H, and Machi G: Comparison of the AUA symptom index in unselected males and females between 55 and 79 years of age. Urology 42: 36-40, 1993.
12. Schafer W, Nopponey R, Rubben H, and Lutzeyer W: The value of free flow rate and pressure-flow studies in the routine investigation of BPH patients. Neurourol Urodyn 7: 219-221, 1988.
13. Witjes WPJ, de Wildt MJ, Rosier PFWM, Caris CTM, Debruyne FMJ, and de la Rosette JJMCH: Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 156: 1026-1034, 1996.
14. El Din K, Koch WFRM, de Wildt MJAM, Kiemeney LALM, Debruyne FMJ, and de la Rosette JJMCH: Reliability of the International Prostate Symptom Score in the assessment of patients with lower urinary tract symptoms and/or benign prostatic hyperplasia. J Urol 155: 1959-1964, 1996.
15. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC III, Harris CJ, and Mulley AG Jr: The natural history of patients with benign prostatic hyperplasia diagnosed by North American urologists. J Urol 157: 10-15, 1997.
16. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 45: 406-413, 1995.
17. McConnell JD: Editorial comment on: Lepor H, for the Terazosin Research Group: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology 45: 406-413, 1995.